Prime Therapeutics puts a fourth-quarter 2026 window on a Foundayo diabetes decision
A pipeline tracker says an FDA decision on Foundayo (orforglipron) for type 2 diabetes could come in late 2026, a window that could shape what insurers cover next year.
Prime Therapeutics' August 2026 GLP-1 pipeline update puts a fourth-quarter 2026 window on a possible FDA decision for Foundayo (orforglipron) in type 2 diabetes, after Eli Lilly submitted the medicine in the second quarter of 2026 [1].
The update reports that Lilly filed orforglipron for type 2 diabetes under the Commissioner's National Priority Voucher pilot, a path the tracker associates with a faster review [1]. Based on that filing, Prime estimates that an approval could arrive in the fourth quarter of 2026, the period running from October through December [1].
Prime states in the same update that voucher-based timelines are estimates rather than published PDUFA dates [1]. A PDUFA date is the formal target date the FDA sets for acting on an application; no such date for orforglipron in type 2 diabetes appears in the update and none has been reported [1].
The August update also placed the Mounjaro (tirzepatide) cardiovascular indication in the third quarter of 2026, and the FDA granted that indication on August 27 [1]. The Mounjaro outcome shows one quarter-level window from the same tracker landing in the quarter when the agency acted, but it does not establish when the orforglipron review will finish [1]. Mounjaro is a tirzepatide product; orforglipron is a separate molecule that Lilly is developing in its incretin pipeline [2].
The update does not include clinical trial results, pricing, or launch plans for orforglipron in type 2 diabetes, and it does not say how the medicine would be positioned against existing type 2 diabetes treatments [1]. Those details have not been disclosed in the tracker [1].
Why it matters for patients
For adults with type 2 diabetes, a fourth-quarter decision would add another Lilly option to a market already crowded with GLP-1 and related medicines. But a quarter is a wide window, not a date. An approval decision and a product on pharmacy shelves are different events, and the update does not describe manufacturing, supply, or launch timing [1].
Coverage is the other piece. Prime Therapeutics publishes these updates for health plans and other payers that set formularies, prior authorization rules, and step therapy requirements [1]. Pipeline reports like this one are a planning input for those decisions, which typically come after an approval, not before it. Whether orforglipron would be covered for type 2 diabetes, at what cost to a patient, and under what conditions has not been reported [1].
People already taking semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) are not affected by this filing. Nothing in the update changes the status of those products, and the update does not compare orforglipron with them [1].
What happens next
The fourth-quarter 2026 window runs from October through December, and Prime describes it as an estimate that could shift [1]. The Mounjaro cardiovascular indication, which the same update had placed in the third quarter, was granted by the FDA on August 27 [1]. No formal FDA action date for orforglipron in type 2 diabetes has been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.